Tumor mutational burden as a predictive biomarker for molecularly matched therapy in two independent pan-cancer cohorts

被引：0
|
作者：
Jelas, I [1 ]
de Bortoli, T. [2 ]
Benary, M. [2 ]
Horak, P. [3 ]
Lamping, M. [2 ]
Schaefer, R. [2 ]
Klauschen, F. [2 ]
Tinhofer-Keilholz, I [2 ]
Leyvraz, S. [2 ]
Keller, U. [2 ]
Stenzinger, A.
Froehling, S. [3 ]
Stintzing, S. [1 ,4 ]
Kurzrock, R. [5 ]
Keilholz, U. [2 ]
Rieke, D. [2 ]
机构：
[1] Charite Univ Med Berlin, Klin Hamatol Onkol & Tumorimmunol, Berlin, Germany
[2] Charite Univ Med Berlin, Berlin, Germany
[3] NCT Heidelberg, Heidelberg, Germany
[4] Univ Klinikum Heidelberg, Heidelberg, Germany
[5] Worldwide Innovat Network WIN Assoc WIN Consortiu, Villejuif, France
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V563
引用
收藏
页码：89 / 90
页数：2
相关论文
共 50 条
  • [41] A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients
    Yanhua Tian
    Jiachen Xu
    Qian Chu
    Jianchun Duan
    Jianjun Zhang
    Hua Bai
    Zhenlin Yang
    Wenfeng Fang
    Liangliang Cai
    Rui Wan
    Kailun Fei
    Jie He
    Shugeng Gao
    Li Zhang
    Zhijie Wang
    Jie Wang
    BMC Medicine, 18
  • [42] Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing
    Wang, Hai-Yun
    Deng, Ling
    Li, Ying-Qing
    Zhang, Xiao
    Long, Ya-Kang
    Zhang, Xu
    Feng, Yan-Fen
    He, Yuan
    Tang, Tao
    Yang, Xin-Hua
    Wang, Fang
    CANCER RESEARCH AND TREATMENT, 2021, 53 (04): : 973 - 982
  • [43] Pan-cancer analysis of biallelic inactivation in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer
    Zucker, Mark
    Perry, Maria A.
    Gould, Samuel I.
    Elkrief, Arielle
    Safonov, Anton
    Thummalapalli, Rohit
    Mehine, Miika
    Chakravarty, Debyani
    Brannon, A. Rose
    Ladanyi, Marc
    Razavi, Pedram
    Donoghue, Mark T. A.
    Murciano-Goroff, Yonina R.
    Grigoriadis, Kristiana
    Mcgranahan, Nicholas
    Jamal-Hanjani, Mariam
    Swanton, Charles
    Chen, Yuan
    Shen, Ronglai
    Chandarlapaty, Sarat
    Solit, David B.
    Schultz, Nikolaus
    Berger, Michael F.
    Chang, Jason
    Schoenfeld, Adam J.
    Sanchez-Rivera, Francisco J.
    Reznik, Ed
    Bandlamudi, Chaitanya
    CELL, 2025, 188 (03) : 851 - 867.e17
  • [44] Tumor Mutation Burden Computation in Two Pan-Cancer Precision Medicine Next-Generation Sequencing Panels
    Shu, Yongqian
    Wu, Xiaohong
    Shen, Jia
    Luo, Dongdong
    Li, Xiang
    Wang, Hailong
    Tang, Yuanhua Tom
    JOURNAL OF COMPUTATIONAL BIOLOGY, 2020, 27 (10) : 1553 - 1560
  • [45] Role of synthetic lethal mutations for the immune response: Exploratory studies of two nonsmall cell lung cancer cohorts and two pan-cancer cohorts
    Wang, Jun
    Liu, Miao
    Zhang, Ding
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer
    Liddell, Savannah S.
    Chakrabarti, Sakti
    Wintheiser, Grant A.
    Zemla, Tyler J.
    Shi, Qian
    Tella, Sri Harsha
    Jin, Zhaohui
    Wookey, Vanessa B.
    Hassan, Hind
    Tran, Nguyen H.
    Borad, Mitesh J.
    Mahipal, Amit
    JCO PRECISION ONCOLOGY, 2022, 6
  • [47] Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?
    Heeke, Simon
    Hofman, Paul
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (06) : 631 - 638
  • [48] Methylated circulating tumor DNA (cfMeDIP) as a predictive biomarker of clinical outcome in pan-cancer patients (pts) treated with pembrolizumab (P)
    Garcia, Enrique Sanz
    Zhao, Eric Y.
    Liu, Zhihui Amy
    Marsh, Kayla
    Razak, Albiruni Ryan Abdul
    Spreafico, Anna
    Bedard, Philippe L.
    Hansen, Aaron Richard
    Lheureux, Stephanie
    Torti, Dax
    Lam, Bernard
    Pugh, Trevor John
    Siu, Lillian L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] Pan-cancer analyses reveal GTSE1 as a biomarker for the immunosuppressive tumor microenvironment
    Tan, Ke
    Fang, Zixuan
    Kong, Lingzhen
    Cheng, Chen
    Hwang, Sydney
    Xu, Min
    MEDICINE, 2023, 102 (34) : E34996
  • [50] Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy
    Bryan H. Louie
    Shumei Kato
    Ki Hwan Kim
    Hyo Jeong Lim
    Ryosuke Okamura
    Ramez N. Eskander
    Gregory Botta
    Hitendra Patel
    Suzanna Lee
    Scott M. Lippman
    Jason K. Sicklick
    Razelle Kurzrock
    npj Precision Oncology, 6
12345